Cue Biopharma, Inc. (CUE): Price and Financial Metrics


Cue Biopharma, Inc. (CUE)

Today's Latest Price: $11.14 USD

0.96 (-7.93%)

Updated Oct 30 4:00pm

Add CUE to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CUE Stock Summary

  • CUE's went public 2.83 years ago, making it older than only 8.21% of listed US stocks we're tracking.
  • CUE's price/sales ratio is 81.98; that's higher than the P/S ratio of 96.94% of US stocks.
  • Revenue growth over the past 12 months for Cue Biopharma Inc comes in at 81.82%, a number that bests 93.48% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CUE, based on their financial statements, market capitalization, and price volatility, are ARVN, ZYME, ACRS, CLLS, and RESN.
  • Visit CUE's SEC page to see the company's official filings. To visit the company's web site, go to www.cuebiopharma.com.

CUE Stock Price Chart Interactive Chart >

Price chart for CUE

CUE Price/Volume Stats

Current price $11.14 52-week high $31.69
Prev. close $12.10 52-week low $8.30
Day low $10.75 Volume 399,000
Day high $12.23 Avg. volume 291,118
50-day MA $15.83 Dividend yield N/A
200-day MA $19.51 Market Cap 328.59M

Cue Biopharma, Inc. (CUE) Company Bio


Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


CUE Latest News Stream


Event/Time News Detail
Loading, please wait...

CUE Latest Social Stream


Loading social stream, please wait...

View Full CUE Social Stream

Latest CUE News From Around the Web

Below are the latest news stories about Cue Biopharma Inc that investors may wish to consider to help them evaluate CUE as an investment opportunity.

Cue Biopharma, Inc. (CUE) CEO Dan Passeri on Q2 2020 Results - Earnings Call Transcript

Cue Biopharma, Inc. (CUE) Q2 2020 Results Earnings Conference Call August 31, 2020, 04:30 PM ET Company Participants George Zavoico - Vice President, Investor Relations & Corporate Development Dan Passeri - President and Chief Executive Officer Anish Suri - Chief Scientific Officer Ken Pienta - Acting Chief Medical Officer Kerri-Ann...

SA Transcripts on Seeking Alpha | September 1, 2020

Cue Biopharma EPS beats by $0.05, misses on revenue

Cue Biopharma (CUE): Q2 GAAP EPS of -$0.38 beats by $0.05.Revenue of $1.08M (+2.9% Y/Y) misses by $0.16M.Press Release...

Seeking Alpha | August 31, 2020

Cue Biopharma Announces PLOS One Publication Demonstrating the Generation and Evaluation of Novel Molecules with Directed Mutations within the B7 Superfamily

- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort.

Yahoo | July 8, 2020

Here's What Cue Biopharma, Inc.'s (NASDAQ:CUE) Shareholder Ownership Structure Looks Like

Every investor in Cue Biopharma, Inc. (NASDAQ:CUE) should be aware of the most powerful shareholder groups. Large...

Yahoo | July 6, 2020

Hedge Funds Have Never Been This Bullish On Cue Biopharma, Inc. (CUE)

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | June 28, 2020

Read More 'CUE' Stories Here

CUE Price Returns

1-mo -28.64%
3-mo -41.09%
6-mo -54.23%
1-year 29.08%
3-year N/A
5-year N/A
YTD -29.83%
2019 237.77%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching CUE

Here are a few links from around the web to help you further your research on Cue Biopharma Inc's stock as an investment opportunity:

Cue Biopharma Inc (CUE) Stock Price | Nasdaq
Cue Biopharma Inc (CUE) Stock Quote, History and News - Yahoo Finance
Cue Biopharma Inc (CUE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7257 seconds.